Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthesis pathway, serving as the catalyst to oxidize the dihydroorotate to orotic acid in the biosynthesis of uridine monophosphate (UMP). Both autoimmune diseases and malaria have been known to be affected by DHODH.
DHODHs are divided into two families based on localization and the electron acceptor: While family 2 members are membrane proteins localized to the inner mitochondrial membrane, family 1 members are soluble proteins localized to the cytosol. Families 1A and 1B, which use fumarate and NAD+ as their respective electron acceptors, are further divided into families 1. Respiratory quinones are used by DHODH enzymes in family 2 as electron acceptors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V34089 | ASLAN003 | 1035688-66-4 | ASLAN003 is a novel, potent and orally bioavailable inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) which has the potential to be first-in-class in AML (Acute Myelogenous Leukemia). |
|
V117566 | DHODH-IN-31 | DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 0.59 μM. | |
|
V116490 | DHODH-IN-32 | DHODH-IN-32 (compound A1) is a DHODH inhibitor. | |
|
V115728 | DHODH-IN-34 | 1644156-93-3 | DHODH-IN-34 (compound 21q) is a potent inhibitor of human dihydroorotate dehydrogenase (DHODH) with an IC50 value of 13 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
